I believe the sales of Marqibo by Acrotech can trigger milestone payments of these secondary CVRs to Spectrum Pharma (or directly to the transfer agent managing our primary CVRs) if within the next four years only since:
"The milestone period lasts for five years post the closing of the transaction"
Similarly, CASI partners with Spectrum for the China region but I do not see any progress with clinical trials there for approval and generating sales.
"In March 2019, the Company received NMPA’s approval of the Company’s Clinical Trial Application (CTA) to allow for a trial to evaluate its efficacy and safety. However, due to the evolving standard of care environment, the rare and niche indication for this product, and our commitment to prioritize resources for our other programs, the Company considers this product to be non-core and is currently evaluating its options for this product."
News 
Market Data 
Discover 
